Intelligent Bio Solutions

Intelligent Bio Solutions

Intelligent Bio Solutions was incorporated in 2016 and currently operates under President and CEO Harry Simeonidis, a former executive at General Electric and Spectranetics. The firm's public listing on Nasdaq under the ticker INBS gives it regulatory visibility atypical of early-stage diagnostic companies. Its foundational technology emerged from university research into sweat-based metabolite detection, later commercialized through a subsidiary inherited from a previous corporate structure — an origin that explains the unusual pairing of British operational roots with a New York headquarters. The company's core asset is the Intelligent Fingerprinting Drug Screening System, a cart-based reader that analyzes fingerprint sweat to detect opioids, cocaine, methamphetamine, and cannabis within ten minutes. Deployment is concentrated in safety-critical industries: construction, transportation, and manufacturing. Named end users include UK-based infrastructure contractors and Australian mining operators bound by workplace safety regulations. The system competes against laboratory urinalysis — offering faster turnaround and eliminating the need for specialized collection facilities. Revenue in fiscal 2024 reached $3.1 million, up from $1.3 million the prior year, driven by cartridge sales and reader placements (per the firm, September 2024). The company has also explored lateral-flow antibody tests through an early-stage subsidiary, though commercialization efforts remain nascent. The firm operated with 52 employees as of the September 2024 annual report, down from 65 a year earlier, reflecting cost-reduction measures alongside a shift toward direct sales in its core UK and Australian markets. Its subsidiary, Intelligent Fingerprinting Limited, based in Cambridge, England, houses the primary R&D and manufacturing operations. A secondary product line — a lateral-flow immunoassay platform — targets point-of-care infectious disease screening but has not contributed materially to revenue. In May 2024, the company completed a 1-for-20 reverse stock split to regain Nasdaq compliance after its share price had languished below the minimum bid threshold, a defensive move that reset its capital structure without altering underlying operations. The genuine structural differentiator is the company's sweat-based diagnostic patent estate, which grants it a protected niche in the workplace drug-testing market. Unlike urine or oral-fluid competitors, the fingerprint method does not require a trained collector or a private bathroom — a practical advantage for remote mine sites and construction yards. Succession risk concentrates on Harry Simeonidis, who serves as both CEO and the primary external face of the technology. The firm's small revenue base and Nasdaq micro-cap status make it an acquisition target for larger diagnostics consolidators, a vulnerability that itself defines its posture as a platform rather than a standalone enterprise.